Ng LM, Jove R, Vande Woude GF. Requirement of Stat3 signaling for HGF/SF-Met mediated tumorigenesis. Oncogene. 2002;21(two):217?26. eight. Trusolino L, Bertotti A, Comoglio PM. MET signalling: principles and functions in improvement, organ regeneration and cancer. Nat Rev Mol Cell Biol. 2010;11(12):834?48. 9. Schmidt C, Bladt F, Goedecke S, et al. Scatter factor/hepatocyte development factor is essential for liver improvement. Nature. 1995;373(6516): 699?02. ten. Uehara Y, Minowa O, Mori C, et al. Placental defect and embryonic lethality in mice lacking hepatocyte growth factor/scatter aspect. Nature. 1995;373(6516):702?05. 11. Maina F, Hilton MC, Ponzetto C, Davies AM, Klein R. Met receptor signaling is necessary for sensory nerve development and HGF promotes axonal growth and survival of sensory neurons. Genes Dev. 1997;11(24):3341?350. 12. Bladt F, Riethmacher D, Isenmann S, Aguzzi A, Birchmeier C. Critical role for the c-met receptor within the migration of myogenic precursor cells into the limb bud. Nature. 1995;376(6543):768?71. 13. Chmielowiec J, Borowiak M, Morkel M, et al. c-Met is essential for wound healing within the skin. J Cell Biol. 2007;177(1):151?62. 14. Huh CG, Aspect VM, S chez A, Uchida K, Conner EA, Thorgeirsson SS. Hepatocyte growth factor/c-met signaling pathway is essential for efficient liver regeneration and repair. Proc Natl Acad Sci U S A. 2004;101(13):4477?482. 15. Liu Y. Hepatocyte development factor in kidney fibrosis: therapeutic prospective and mechanisms of action. Am J Physiol Renal Physiol. 2004;287(1):F7 16. 16. Schmidt L, Duh FM, Chen F, et al. Germline and somatic mutations in the tyrosine kinase domain in the MET proto-oncogene in papillary renal carcinomas. Nat Genet. 1997;16(1):68?three. 17. Graveel CR, London CA, Vande Woude GF. A mouse model of activating Met mutations. Cell Cycle. 2005;4(four):518?20. 18. Nakajima M, Sawada H, Yamada Y, et al. The prognostic significance of amplification and overexpression of c-met and c-erb B-2 in human gastric carcinomas. Cancer. 1999;85(9):1894?902. 19. Kuniyasu H, Yasui W, Kitadai Y, Yokozaki H, Ito H, Tahara E.6-(Diphenylphosphino)-2,2′-bipyridine Price Frequent amplification in the c-met gene in scirrhous form stomach cancer.4-(Aminomethyl)pyrimidine structure Biochem Biophys Res Commun. 1992;189(1):227?32.PMID:24834360 20. Fischer U, M ler HW, Sattler HP, Feiden K, Zang KD, Meese E. Amplification of your MET gene in glioma. Genes Chromosomes Cancer. 1995;12(1):63?5. 21. Samuelson E, Levan K, Adamovic T, Levan G, Horvath G. Recurrent gene amplifications in human form I endometrial adenocarcinoma detected by fluorescence in situ hybridization. Cancer Genet Cytogenet. 2008;181(1):25?0. 22. Beau-Faller M, Ruppert AM, Voegeli AC, et al. MET gene copy quantity in non-small cell lung cancer: molecular analysis in a targeted tyrosine kinase inhibitor na e cohort. J Thorac Oncol. 2008;three(four):331?39. 23. Zeng ZS, Weiser MR, Kuntz E, et al. c-Met gene amplification is related to advanced stage colorectal cancer and liver metastases. Cancer Lett. 2008;265(2):258?69. 24. Scagliotti GV Novello S, von Pawel J. The emerging part of MET/ , HGF inhibitors in oncology. Cancer Treat Rev. 2013;39(7):793?01. 25. Dulak AM, Gubish CT, Stabile LP, Henry C, Siegfried JM. HGFindependent potentiation of EGFR action by c-Met. Oncogene. 2011; 30(33):3625?635. 26. Engelman JA, Zejnullahu K, Mitsudomi T, et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science. 2007;316(5827):1039?043. OncoTargets and Therapy 2014:Conclusion and future directionsThe ubiqui.
